The 3rd Edition of the Immuno-Oncology & Biomarker Summit, organised by Veridon Global, will convene in Basel, Switzerland on 11–12 March 2027, bringing together senior leaders from pharma, biotech, diagnostics, CROs, academia and technology to advance cancer research, biomarker discovery and precision immuno-oncology.
Why Basel? A Strategic Move to Europe’s Pharma Hub
Following the successful London edition and valuable feedback from delegates, speakers and partners, Veridon Global has relocated the summit to Basel – widely recognised as the epicentre of the European pharmaceutical and biotech industry. This strategic shift places the event at the heart of a dense ecosystem of global pharma headquarters, innovative biotechs, leading academic medical centres and cutting-edge diagnostics companies, facilitating deeper industry engagement and more meaningful collaborations.
Event Vision: Quality Over Quantity
Unlike large oncology congresses that prioritise scale, the Immuno-Oncology & Biomarker Summit is intentionally designed around quality of interaction rather than quantity of attendees. The summit will host a small, curated audience of senior industry professionals, creating an intimate environment where participants can engage in substantive conversations, exchange real-world experience and forge valuable business connections. This format addresses a common pain point at major conferences – the difficulty of securing meaningful face time with peers and potential partners amidst crowded halls and packed schedules.
Who Will Attend?
The summit is expected to attract a diverse, high-calibre cohort including:
- Pharmaceutical and biotech company executives and R&D leaders
- Diagnostics and companion diagnostics developers
- Contract research organisations (CROs)
- Academic research centres and translational medicine teams
- Technology companies enabling biomarker discovery, AI-driven oncology and digital pathology
This cross-sector representation ensures discussions span the full drug development lifecycle – from target identification and biomarker validation through clinical trial design, regulatory strategy and commercialisation.
Programme Highlights: Beyond Traditional Presentations
The 2027 programme will feature a dynamic mix of formats designed to maximise engagement and knowledge exchange:
Expert presentations on latest advances in immuno-oncology mechanisms, resistance pathways and next-generation therapies
- Panel discussions tackling hot topics such as biomarker-driven trial design, companion diagnostics co-development and regulatory harmonisation
- Interactive roundtables for deep-dive problem solving on specific challenges in translational oncology
- Structured networking sessions to connect attendees with shared interests
- Pre-arranged one-to-one meetings enabling targeted business development and partnership discussions
This multi-format approach ensures attendees leave with both cutting-edge scientific insights and actionable business opportunities.
Key Themes Expected at the Summit
While the full 2027 agenda is still being finalised, previous editions and related industry events point to several core themes likely to feature prominently:
Immuno-Oncology Innovation
- Novel immune checkpoint targets and first-in-class assets
- Engineering advanced cell and gene therapies for solid tumours
- Overcoming resistance mechanisms and tumour microenvironment challenges
- Neoadjuvant and adjuvant immunotherapy strategies
Biomarker Discovery & Validation
- Next-generation biomarker platforms: liquid biopsy, multi-omics and spatial transcriptomics
- Predictive and prognostic biomarkers for patient selection and minimal residual disease (MRD) monitoring
- Biomarker validation strategies for clinical trial success and regulatory qualification
- Companion diagnostics co-development from discovery to approval
Translational & Clinical Acceleration
- AI-driven drug discovery and biomarker modelling
- Adaptive, biomarker-driven clinical trial designs
- Translating early immuno-oncology science into Phase II success
- Regulatory harmonisation for biomarker qualification across regions
Registration and Participation
Organised by Veridon Global, the summit is positioned as a must-attend event for senior professionals seeking to stay ahead in the rapidly evolving immuno-oncology and biomarker landscape. The small-scale, high-interaction format makes it particularly valuable for those looking to establish new collaborations, benchmark strategies against peers or explore partnership opportunities in precision oncology.
For organisations active in cancer research, biomarker development or immuno-oncology therapeutics, the 3rd Edition in Basel offers a focused, high-value platform to shape the future of precision cancer medicine.